In this article, we will discuss Plerixafor (Dosage Overview). So, let’s get started.
Plerixafor is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).
Recommended Dosage and Admiistration
Vials should be inspected visually for particulate matter and discoloration prior to
administration and should not be used if there is particulate matter or if the solution is discolored. Begin treatment with Plerixafor after the patient has received G-CSF once daily for four days. Administer Plerixafor approximately 11 hours prior to initiation of each apheresis for up to 4 consecutive days.
The recommended dose of Plerixafor is 0.24 mg/kg body weight by subcutaneous (SC)
injection. Use the patient’s actual body weight to calculate the volume of Plerixafor to be administered. Each vial delivers 1.2 mL of 20 mg/mL solution, and the volume to be administered to patients should be calculated from the following equation: 0.012 X patient’s actual body weight (in kg) = volume to be administered (in mL)
In clinical studies, Plerixafor dose has been calculated based on actual body weight in
patients up to 175% of ideal body weight. Plerixafor dose and treatment of patients
weighing more than 175% of ideal body weight have not been investigated.
Based on increasing exposure with increasing body weight, the plerixafor dose should not exceed 40 mg/day.